JP2004524349A5 - - Google Patents

Download PDF

Info

Publication number
JP2004524349A5
JP2004524349A5 JP2002576233A JP2002576233A JP2004524349A5 JP 2004524349 A5 JP2004524349 A5 JP 2004524349A5 JP 2002576233 A JP2002576233 A JP 2002576233A JP 2002576233 A JP2002576233 A JP 2002576233A JP 2004524349 A5 JP2004524349 A5 JP 2004524349A5
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
amino
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2002576233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004524349A (ja
Filing date
Publication date
Priority claimed from FR0103916A external-priority patent/FR2822468B1/fr
Application filed filed Critical
Priority claimed from PCT/FR2002/001005 external-priority patent/WO2002076975A1/fr
Publication of JP2004524349A publication Critical patent/JP2004524349A/ja
Publication of JP2004524349A5 publication Critical patent/JP2004524349A5/ja
Ceased legal-status Critical Current

Links

JP2002576233A 2001-03-23 2002-03-22 化学的誘導体および抗テロメラーゼ剤としてのその使用 Ceased JP2004524349A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0103916A FR2822468B1 (fr) 2001-03-23 2001-03-23 Derives chimiques et leur application comme agent anti-telomerase
FR0110370 2001-08-02
PCT/FR2002/001005 WO2002076975A1 (fr) 2001-03-23 2002-03-22 Derives chimiques et leur application comme agent antitelomerase

Publications (2)

Publication Number Publication Date
JP2004524349A JP2004524349A (ja) 2004-08-12
JP2004524349A5 true JP2004524349A5 (enExample) 2005-12-22

Family

ID=26212933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002576233A Ceased JP2004524349A (ja) 2001-03-23 2002-03-22 化学的誘導体および抗テロメラーゼ剤としてのその使用

Country Status (11)

Country Link
EP (1) EP1373252A1 (enExample)
JP (1) JP2004524349A (enExample)
AR (1) AR034297A1 (enExample)
AU (1) AU2002251140B2 (enExample)
CA (1) CA2442012A1 (enExample)
CO (1) CO5380035A1 (enExample)
IL (2) IL158056A0 (enExample)
MX (1) MXPA03008269A (enExample)
MY (1) MY130957A (enExample)
PE (1) PE20020959A1 (enExample)
WO (1) WO2002076975A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004001018A2 (en) * 2002-06-25 2003-12-31 The Center For Blood Research, Inc. Vacuolins
FR2850970B1 (fr) * 2003-02-07 2006-07-07 Aventis Pharma Sa Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2608463C (en) * 2005-05-19 2015-02-03 Prometic Biosciences Inc. Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
KR20100038108A (ko) * 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 트리아진 키나제 억제제
FR2948686B1 (fr) * 2009-07-30 2011-08-19 Biomerieux Sa Nouveaux substrats de peptidase
US20210024455A1 (en) * 2018-03-20 2021-01-28 Hiroshima University Compound which inhibits telomere-binding protein, and telomere-binding protein inhibitor containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
IL149402A0 (en) * 1999-11-29 2002-11-10 Aventis Pharma Sa Arylamine derivatives and their use as anti-telomerase agent
AU2003244463A1 (en) * 2002-02-05 2003-09-02 Yamanouchi Pharmaceutical Co., Ltd. 2,4,6-triamino-1,3,5-triazine derivative

Similar Documents

Publication Publication Date Title
JP2004524349A5 (enExample)
RU2376287C2 (ru) Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac
JP5042888B2 (ja) Jakおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
US20210404012A1 (en) Inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease
ITMI992711A1 (it) Composti organici
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
JP2014500295A5 (enExample)
JP2011529474A (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
MXPA04000905A (es) Derivados de amino-ftalazinona activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
JP2011520832A5 (enExample)
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
JP2020505433A5 (enExample)
JP2015530975A (ja) 置換型ピラゾロン化合物及び使用方法
CA2369560A1 (en) Agent for prophylaxis and treatment of liver disease
JP2004511512A5 (enExample)
TW200510385A (en) Pyrrolo[3, 4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP2020516693A5 (enExample)
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
TW202033191A (zh) 新穎藥物組成物及其用途
TW200831075A (en) Combination
RU2019125177A (ru) Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение
CA2198005A1 (en) Pyrazolo[3,4-g]quinoxaline compounds which inhibit pdgf receptor protein tyrosine kinase
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
IL158056A (en) Chemical derivatives and pharmaceutical compositions containing them for use as anti-telomerase agent